RITUXAN after a relapse in your CLL journey
If you have already been treated for CLL and have a relapse, RITUXAN plus FC chemotherapy may be able to help. These drugs work in different ways to find and attack the cells where cancer starts.
RITUXAN targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. Once attached to the CD20 protein, RITUXAN is thought to work in different ways including:
- By helping your own immune system destroy the cancer cells
- By destroying the cancer cells on its own
In addition, RITUXAN can also harm healthy cells in your body.
FC chemotherapy attacks fast-growing cells. These include cancer cells and healthy cells like hair and the lining of your intestines.
Combining RITUXAN with FC chemotherapy may improve CLL treatment response.
In one study, previously treated patients who received RITUXAN plus FC chemotherapy experienced an average of 2.2 years without their cancer advancing, compared to 1.8 years with FC chemotherapy by itself. Fifty-four percent of patients who received RITUXAN plus FC chemotherapy after relapse went into either partial or complete remission for a period of time, compared with 45% of patients who received FC chemotherapy by itself. These results were from a clinical trial and may not be the same as what you experience.
You will have up to 6 cycles, or rounds, of treatment. You will be given RITUXAN and FC chemotherapy at the beginning of each cycle. Each cycle is 28 days.
- For Cycle 1, RITUXAN and
FC chemotherapy are given on different days:
- Your RITUXAN infusion is on the day before the 28-day cycle starts
- In the first 3 days of the 28-day cycle, you will receive FC chemotherapy
- For Cycles 2 through 6, RITUXAN
and FC chemotherapy are given on the first day of each cycle. FC
chemotherapy will also be given on Days 2 and 3
A full course of RITUXAN plus FC chemotherapy will take approximately 6 months to complete.
Relapse therapy infusion schedule for CLL
Select Important Safety Information
RITUXAN for the treatment of CD20-positive chronic lymphocytic leukemia in combination with FC chemotherapy as a treatment after disease has recurred
Severe side effects reported more often in patients receiving RITUXAN and FC chemotherapy vs. FC chemotherapy alone were infusion reactions; decreased blood cell counts, including decreases in white blood cells with or without a fever and platelets; low blood pressure; and hepatitis B. Severe side effects reported more commonly in the elderly (≥70 years of age) versus younger patients were infections; decreased blood cell counts, including decreases in white blood cells with or without a fever, red blood cells, and platelets.
REACH Treatment Considerations
Chronic lymphocytic leukemia patients 65 years of age or older were not shown to benefit from RITUXAN in combination with FC chemotherapy as a treatment after disease has recurred.
RITUXAN is available by prescription only.